vs
Side-by-side financial comparison of El Pollo Loco Holdings, Inc. (LOCO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $126.2M, roughly 1.4× El Pollo Loco Holdings, Inc.). El Pollo Loco Holdings, Inc. runs the higher net margin — 6.5% vs 1.6%, a 4.8% gap on every dollar of revenue. On growth, El Pollo Loco Holdings, Inc. posted the faster year-over-year revenue change (5.9% vs 5.0%). Over the past eight quarters, El Pollo Loco Holdings, Inc.'s revenue compounded faster (1.6% CAGR vs -0.2%).
El Pollo Loco, Inc., is a restaurant chain based in the United States, specializing in Mexican-style grilled chicken. Restaurant service consists of dine-in and take-out, with some locations offering drive-through options. The company is headquartered in Costa Mesa, California, and operates about 500 company-owned and franchised restaurants in the Southwestern United States.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LOCO vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $126.2M | $177.4M |
| Net Profit | $8.2M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 9.7% | 3.9% |
| Net Margin | 6.5% | 1.6% |
| Revenue YoY | 5.9% | 5.0% |
| Net Profit YoY | 48.8% | — |
| EPS (diluted) | $0.27 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $126.2M | $177.4M | ||
| Q4 25 | $123.5M | $196.9M | ||
| Q3 25 | $121.5M | $179.5M | ||
| Q2 25 | $125.8M | $181.1M | ||
| Q1 25 | $119.2M | $168.9M | ||
| Q4 24 | $114.3M | $187.3M | ||
| Q3 24 | $120.4M | $168.6M | ||
| Q2 24 | $122.2M | $178.0M |
| Q1 26 | $8.2M | $2.9M | ||
| Q4 25 | $6.5M | — | ||
| Q3 25 | $7.4M | $5.4M | ||
| Q2 25 | $7.1M | $-4.8M | ||
| Q1 25 | $5.5M | $4.8M | ||
| Q4 24 | $6.0M | — | ||
| Q3 24 | $6.2M | $-143.5M | ||
| Q2 24 | $7.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 9.7% | 3.9% | ||
| Q4 25 | 8.3% | 1.2% | ||
| Q3 25 | 9.4% | 3.5% | ||
| Q2 25 | 9.0% | 4.7% | ||
| Q1 25 | 7.5% | 1.2% | ||
| Q4 24 | 7.9% | 13.2% | ||
| Q3 24 | 8.4% | -82.8% | ||
| Q2 24 | 10.1% | 15.9% |
| Q1 26 | 6.5% | 1.6% | ||
| Q4 25 | 5.3% | — | ||
| Q3 25 | 6.1% | 3.0% | ||
| Q2 25 | 5.6% | -2.7% | ||
| Q1 25 | 4.6% | 2.8% | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 5.1% | -85.1% | ||
| Q2 24 | 6.2% | 10.6% |
| Q1 26 | $0.27 | $0.07 | ||
| Q4 25 | $0.22 | $0.05 | ||
| Q3 25 | $0.25 | $0.12 | ||
| Q2 25 | $0.24 | $-0.11 | ||
| Q1 25 | $0.19 | $0.10 | ||
| Q4 24 | $0.21 | $0.38 | ||
| Q3 24 | $0.21 | $-3.11 | ||
| Q2 24 | $0.25 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $302.5M | $653.9M |
| Total Assets | $609.1M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.9M | $144.3M | ||
| Q4 25 | $6.2M | $238.4M | ||
| Q3 25 | $10.9M | $246.3M | ||
| Q2 25 | $9.0M | $445.9M | ||
| Q1 25 | $4.3M | $493.6M | ||
| Q4 24 | $2.5M | $484.6M | ||
| Q3 24 | $7.9M | $453.8M | ||
| Q2 24 | $10.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $51.0M | $372.2M | ||
| Q3 25 | $61.0M | $376.7M | ||
| Q2 25 | $69.0M | $580.5M | ||
| Q1 25 | $73.0M | $583.4M | ||
| Q4 24 | $71.0M | $585.3M | ||
| Q3 24 | $76.0M | — | ||
| Q2 24 | $87.0M | — |
| Q1 26 | $302.5M | $653.9M | ||
| Q4 25 | $291.1M | $693.1M | ||
| Q3 25 | $282.9M | $727.2M | ||
| Q2 25 | $274.2M | $757.8M | ||
| Q1 25 | $265.7M | $798.5M | ||
| Q4 24 | $260.7M | $778.3M | ||
| Q3 24 | $255.2M | $749.6M | ||
| Q2 24 | $248.6M | $879.3M |
| Q1 26 | $609.1M | $1.2B | ||
| Q4 25 | $606.6M | $1.3B | ||
| Q3 25 | $602.7M | $1.3B | ||
| Q2 25 | $596.8M | $1.5B | ||
| Q1 25 | $590.5M | $1.6B | ||
| Q4 24 | $592.0M | $1.6B | ||
| Q3 24 | $590.0M | $1.5B | ||
| Q2 24 | $593.8M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.18× | 0.54× | ||
| Q3 25 | 0.22× | 0.52× | ||
| Q2 25 | 0.25× | 0.77× | ||
| Q1 25 | 0.27× | 0.73× | ||
| Q4 24 | 0.27× | 0.75× | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOCO
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
